NCT03550950View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

February 5, 2019

Study Completion Date

February 5, 2019

Conditions

Healthy

Interventions

DRUG

JNJ-64232025 IV

JNJ-64232025 will be administered as IV infusion.

DRUG

JNJ-64232025 SC

JNJ-64232025 will be administered as SC injection.

DRUG

Placebo

Matching placebo will be administered as IV infusion or SC injection.

Trial Locations (1)

2060

SGS Life Science Services, Antwerp

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT03550950 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants | Biotech Hunter | Biotech Hunter